Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0613 in Advanced Solid Tumors
NCT07618260Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0613 in solid tumor (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Safety and tolerability at 2 years, Dose-limiting toxicity at 21 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
SIM0613
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07618260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618260.